Synopsis
Join us for a webinar in partnership with the New Jersey Association for Biomedical Research!
A regulatory turning point is underway in biomedical research and drug development. As agencies, policymakers, and industry leaders increasingly prioritize human-relevant New Approach Methodologies (NAMs), the long-standing reliance on animal testing is being reevaluated. This shift creates an urgent need for scalable, reproducible, and biologically relevant models that can better predict human responses while advancing the principles of the 3Rs: replacement, reduction, and refinement of animal use.
Organ-on-a-Chip technology offers a powerful path forward. By recreating key aspects of human tissue, function, and dynamic microphysiology, Organ-Chips provide experimental models designed to bridge the translational gap between conventional in vitro systems and human outcomes. Among the most clinically important applications is drug-induced liver injury, a major cause of drug development failure and post-market safety concern.
This presentation will introduce the key concepts of Organ-on-a-Chip technology and how it provides a more in vivo-relevant platform for modeling human biology and predicting clinical outcomes, including the use of Emulate’s Liver-Chip for predicting drug-induced liver toxicity. The discussion will highlight how Liver-Chip studies have demonstrated the ability to identify hepatotoxic risk and support more predictive preclinical safety assessment.
The session will also explore how Emulate is turning the promise of Organ-on-a-Chip technology into routine practice through the launch of its AVA™ Emulation System. By integrating incubation, microfluidic culture, imaging, and automation-ready workflows in a high-throughput platform, AVA is designed to overcome key barriers that have historically limited Organ-Chip adoption. Together, the Liver-Chip and AVA represent a path toward making Organ-on-a-Chip assays standard tools in pharmaceutical development—supporting more human-relevant decision-making while advancing the reduction and replacement of animal testing.
